Show simple item record

dc.contributor.authorChami, Goyletteen
dc.contributor.authorBundy, Donald APen
dc.date.accessioned2019-03-20T00:30:15Z
dc.date.available2019-03-20T00:30:15Z
dc.date.issued2019-09en
dc.identifier.issn1473-3099
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/290652
dc.description.abstractNeglected tropical diseases afflict more than one billion of the world’s poorest people. Annual pharmaceutical donations of billions of preventive chemotherapies for neglected tropical diseases enable the largest en masse treatment campaigns globally with respect to the number of people targeted for treatment. However, the blanket distribution of medicines at no cost to individuals in need of treatment does not guarantee that those individuals are treated. Here we argue that the expansion of medicine donations programmes and the development of new medicines are not the primary solutions to sustaining and expanding the growth of neglected tropical disease programmes. Treatment often is not verified; access to medicines may not be equitable across at-risk populations; and treatment targets for disease control remain largely unmet within many endemic countries. For the more equitable access to and efficient use of existing medicines, research is needed now on how best to integrate the treatment of neglected tropical diseases into local health systems. A comprehensive approach should be employed that combines mass drug administration with on-demand access to treatment. Increased endemic country commitment to and ownership of treatment campaigns is essential to improve the access to medicines for neglected tropical diseases.
dc.description.sponsorshipWellcome Trust
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherThe Lancet Publishing Group
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumansen
dc.subjectPharmaceutical Preparationsen
dc.subjectTropical Medicineen
dc.subjectHealth Services Accessibilityen
dc.subjectHealthcare Disparitiesen
dc.subjectNeglected Diseasesen
dc.subjectMass Drug Administrationen
dc.titleMore medicines alone cannot ensure the treatment of neglected tropical diseases.en
dc.typeArticle
prism.endingPagee336
prism.issueIdentifier9en
prism.publicationDate2019en
prism.publicationNameThe Lancet. Infectious diseasesen
prism.startingPagee330
prism.volume19en
dc.identifier.doi10.17863/CAM.37859
dcterms.dateAccepted2019-03-13en
rioxxterms.versionofrecord10.1016/s1473-3099(19)30160-4en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-09en
dc.contributor.orcidChami, Goylette [0000-0002-4653-0846]
dc.identifier.eissn1474-4457
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idWellcome Trust (100891/Z/13/Z)
pubs.funder-project-idWellcome Trust (083931/Z/07/Z)
cam.orpheus.successThu Jan 30 10:49:51 GMT 2020 - Embargo updated*
rioxxterms.freetoread.startdate2020-03-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International